CAMP4 expects to dose first patients in a Phase 1-2 SYNGAP1 study by the end of the year, with data in the first half of 28. It ended Q3 with $124,500,000, providing runway through 2028 to advance Shank 3.
CAMP · Camp4 Therapeutics Corp
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
The ASCEND Phase 1/2 clinical trial is expected to dose its first patient in the fourth quarter of 2026. Cash and cash equivalents were $124.5 million on September 30, 2026, expected to fund operations through the end of 2028.
CAMP4 Therapeutics launched the ASCEND Phase 1/2 clinical trial of CMP-002 for SYNGAP1-related disorder and remains on track to dose the first patient by year-end 2026. It reported $124.5 million in cash and a $29.0 million quarterly net loss.
CAMP4 THERAPEUTICS CORPORATION expects to dose the first patient in its ASCEND trial of CMP-002 by the end of 2026 and targets topline data in the first half of 2028. It also expects a SHANK3 development candidate in 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CAMP
this stock
Camp4 Therapeutics Corp
|
$242.23M | -37.0% | +436.5% | — | 5.2% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.35B | +18.6% | +46.2% | 34.6 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.52B | +23.4% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$83.08B | +630.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$65.26B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 9, 2026
- This year
- 23
CAMP4 expects to dose first patients in a Phase 1-2 SYNGAP1 study by the end of the year, with data in the first half of 28. It ended Q3 with $124,500,000, providing runway through 2028 to advance Shank 3.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CAMP | -17.7% | +22.9% | -8.3% | -2.5% | -37.0% |
| SPY | -1.7% | -3.5% | -1.4% | -2.1% | +8.5% |
| vs SPY | -16.0% | +26.4% | -6.9% | -0.4% | -45.5% |